Clinical Value of Circulating Mutations for Patients with Metastatic Breast Cancer: a Meta-analysis

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2018 Aug 28

PMID 30147360

Citations 21

Authors

Kai Zhang

Ruoxi Hong

Fei Xu

Wen Xia

Lee Kaping

Ge Qin

Qiufan Zheng

Qianyi Lu

Yan Xia Shi

Zhong Yu Yuan

Shusen Wang

Affiliations

Soon will be listed here.

Abstract

Background: The clinical implication of plasma ESR1 mutations in the estrogen receptor (ER)-positive metastatic breast cancer (MBC) patients who had progressed after prior aromatase inhibitor (AI)-based therapy remains controversial. We conducted the first meta-analysis to investigate the prognostic significance and predictive role of plasma ESR1 mutations in MBC patients with prior exposure to AI therapy.

Materials And Methods: We searched PubMed, Embase, and Cochrane Library databases for eligible studies. Meta-analysis was conducted to calculate combined hazard ratios (HRs) with 95% CIs for progression-free survival (PFS) and overall survival (OS). Subgroup and sensitivity analyses were also performed.

Results: This study enrolled a total of 1,530 patients with ER-positive MBC cases from six articles, including 429 ESR1 mutation carriers (28.04%). Meta-analysis demonstrated that plasma ESR1 mutation carriers had significantly worse PFS (HR: 1.40, 95% CI: 1.17-1.66; <0.0001) and OS (HR: 1.65, 95% CI: 1.36-2.01; <0.0001) compared to wild-type ESR1. Subgroup analysis showed that plasma ESR1 mutations were associated with shorter PFS after AI-based treatment, but were not significantly predictive of outcome on fulvestrant-containing therapy (HR: 1.26, 95% CI: 0.98-1.62; =0.077). As for different ESR1 mutations, D538G mutation implied significantly worse PFS (HR: 1.50, 95% CI: 1.18-1.91; =0.01), while Y537S mutation was not correlated with PFS (HR: 1.65, 95% CI: 0.87-1.73; =0.134).

Conclusion: The meta-analysis indicated that plasma ESR1 mutation assessment may have prognostic significance and clinical value in guiding further endocrine therapy choice in ER+ MBC patients who received prior AI therapy.

Citing Articles

Molecular characterization of colorectal cancer (CRC) using next generation sequencing (NGS) in bridging the gap between research and clinical practice: from biomarker discovery to clinical implementation.

Afolabi H, Salleh S, Zakaria Z, Seng C, Nafi S, Aziz A Discov Oncol. 2025; 16(1):268.

PMID: 40048017 PMC: 11885200. DOI: 10.1007/s12672-025-01960-2.

Co-targeting of metabolism using dietary and pharmacologic approaches reduces breast cancer metastatic burden.

Zuo Q, Yoo J, Nelson E, Sikora M, Riggins R, Madak-Erdogan Z NPJ Breast Cancer. 2025; 11(1):3.

PMID: 39809806 PMC: 11733225. DOI: 10.1038/s41523-024-00715-6.

CDK4/6 Inhibition - Therapy Sequences and the Quest to Find the Best Biomarkers - an Overview of Current Programs.

Schneeweiss A, Brucker S, Huebner H, Volmer L, Hack C, Seitz K Geburtshilfe Frauenheilkd. 2024; 84(5):443-458.

PMID: 38817598 PMC: 11136530. DOI: 10.1055/a-2286-6066.

Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer.

Iwamoto T, Niikura N, Watanabe K, Takeshita T, Kikawa Y, Kobayashi K Breast Cancer Res Treat. 2023; 203(2):225-234.

PMID: 37875670 DOI: 10.1007/s10549-023-07144-2.

Detection of Ultra-Rare Mutations in Primary Breast Cancer Using LNA-Clamp ddPCR.

Hashimoto Y, Masunaga N, Kagara N, Abe K, Yoshinami T, Tsukabe M Cancers (Basel). 2023; 15(9).

PMID: 37174098 PMC: 10177270. DOI: 10.3390/cancers15092632.

References

Schiavon G, Hrebien S, Garcia-Murillas I, Cutts R, Pearson A, Tarazona N . Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med. 2015; 7(313):313ra182. PMC: 4998737. DOI: 10.1126/scitranslmed.aac7551. View

Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D . Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. JAMA Oncol. 2016; 2(10):1310-1315. PMC: 5063698. DOI: 10.1001/jamaoncol.2016.1279. View

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

Yates L, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P . Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med. 2015; 21(7):751-9. PMC: 4500826. DOI: 10.1038/nm.3886. View

Spoerke J, Gendreau S, Walter K, Qiu J, Wilson T, Savage H . Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat Commun. 2016; 7:11579. PMC: 4869259. DOI: 10.1038/ncomms11579. View

Toy W, Shen Y, Won H, Green B, Sakr R, Will M . ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013; 45(12):1439-45. PMC: 3903423. DOI: 10.1038/ng.2822. View

Sundaresan T, Sequist L, Heymach J, Riely G, Janne P, Koch W . Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. Clin Cancer Res. 2015; 22(5):1103-10. PMC: 4775471. DOI: 10.1158/1078-0432.CCR-15-1031. View

Wang E, Zaman N, Mcgee S, Milanese J, Masoudi-Nejad A, OConnor-Mccourt M . Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data. Semin Cancer Biol. 2014; 30:4-12. DOI: 10.1016/j.semcancer.2014.04.002. View

Zou J, Wang E . eTumorType, An Algorithm of Discriminating Cancer Types for Circulating Tumor Cells or Cell-free DNAs in Blood. Genomics Proteomics Bioinformatics. 2017; 15(2):130-140. PMC: 5414714. DOI: 10.1016/j.gpb.2017.01.004. View

10.

Angus L, Beije N, Jager A, Martens J, Sleijfer S . ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients. Cancer Treat Rev. 2016; 52:33-40. DOI: 10.1016/j.ctrv.2016.11.001. View

11.

Guttery D, Page K, Hills A, Woodley L, Marchese S, Rghebi B . Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. Clin Chem. 2015; 61(7):974-82. DOI: 10.1373/clinchem.2015.238717. View

12.

Clatot F, Perdrix A, Augusto L, Beaussire L, Delacour J, Calbrix C . Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor. Oncotarget. 2016; 7(46):74448-74459. PMC: 5342678. DOI: 10.18632/oncotarget.12950. View

13.

Forshew T, Murtaza M, Parkinson C, Gale D, Tsui D, Kaper F . Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012; 4(136):136ra68. DOI: 10.1126/scitranslmed.3003726. View

14.

Burstein H, Prestrud A, Seidenfeld J, Anderson H, Buchholz T, Davidson N . American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010; 28(23):3784-96. PMC: 5569672. DOI: 10.1200/JCO.2009.26.3756. View

15.

Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo A . Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res. 2014; 20(7):1757-1767. PMC: 3998833. DOI: 10.1158/1078-0432.CCR-13-2332. View

16.

Stroup D, Berlin J, Morton S, Olkin I, Williamson G, Rennie D . Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283(15):2008-12. DOI: 10.1001/jama.283.15.2008. View

17.

Li S, Shen D, Shao J, Crowder R, Liu W, Prat A . Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013; 4(6):1116-30. PMC: 3881975. DOI: 10.1016/j.celrep.2013.08.022. View

18.

Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C . Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol. 2011; 30(6):587-92. PMC: 5015424. DOI: 10.1200/JCO.2010.33.5232. View

19.

Fribbens C, OLeary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M . Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. J Clin Oncol. 2016; 34(25):2961-8. DOI: 10.1200/JCO.2016.67.3061. View

20.

McGee S, Tibiche C, Trifiro M, Wang E . Network Analysis Reveals A Signaling Regulatory Loop in the PIK3CA-mutated Breast Cancer Predicting Survival Outcome. Genomics Proteomics Bioinformatics. 2017; 15(2):121-129. PMC: 5414713. DOI: 10.1016/j.gpb.2017.02.002. View